drugset / Trial / NCT00903396

Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer

NCT00903396

RandomizedParallel-groupDouble-blindSupportive care

Summary

RATIONALE: Palonosetron hydrochloride may prevent nausea and vomiting caused by radiation therapy. It is not yet known whether palonosetron hydrochloride is more effective than a placebo in preventing nausea and vomiting. PURPOSE: This randomized phase II trial is studying the side effects of palonosetron hydrochloride and to see how well it works in preventing nausea and vomiting caused by radiation therapy in patients with primary abdominal cancer.

Timeline

Start
2009-09
Primary completion
2011-01
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Palonosetron Other / unclassified Intravenous